Vitrolife interim report January - March 2003

2003-04-23 - 12:07

Vitrolife interim report January - March 2003 · Net sales for core activities increased by 18 % to a total of SEK 25.9 million (22.0). · Gross margin increased and amounted to 62 % (50 %). · The group's net loss totalled SEK -0.6 million (-3.7). · Vitrolife receive USA patent for a new technique for cryo-preservation of living cells, named Vitroloop. Gothenburg, March 23, 2003. Vitrolife AB (Publ) For further information, please contact: Vitrolife Acting CEO: Magnus Nilsson Tel: +46 31 721 80 00 Mobile +46 708 22 80 61 mnilsson@vitrolife.com CFO and IR agent: Margareta Fischer Tel: +46 31 721 80 00 Mobile: +46 708 22 80 13 mfischer@vitrolife.com Vitrolife is a global biomedical corporation that works with products for cell and tissue technology. The Vitrolife group consists of the parent company, Vitrolife AB (Publ) and four wholly owned subsidiaries: Vitrolife Sweden AB (Gothenburg, Sweden), Vitrolife Inc. (Denver, Colorado), A-Life Ltd. (Edinburgh, Scotland), and A-Life Inc. (Newport Beach, California). The group's operations focused on three geographic areas. · Europe/Middle East · North America · Rest of the World Vitrolife's business concept is to develop, produce and sell advanced products and systems for the preparation, cultivation, preservation and support of cells, tissues and organs. ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/04/23/20041110BIT21240/wkr0001.pdf The full interim report in Swedish